Spyre Therapeutics (SYRE) Change in Accured Expenses (2015 - 2026)

Spyre Therapeutics' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 160.9% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (up 1831.96% YoY) and the FY2025 annual result came in at -$764000.0, down 105.23% from the prior year.
• Change in Accured Expenses was $3.7 million for Q1 2026 at Spyre Therapeutics, up from $3.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $14.9 million in Q4 2024 and bottomed at -$15.8 million in Q2 2024.
• A 5-year average of $692000.0 and a median of $450000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 1768.46% in 2024, while the deepest fall reached 849.0% in 2024.
• Spyre Therapeutics' Change in Accured Expenses stood at $450000.0 in 2022, then sank by 298.0% to -$891000.0 in 2023, then jumped by 1768.46% to $14.9 million in 2024, then sank by 78.99% to $3.1 million in 2025, then advanced by 16.93% to $3.7 million in 2026.
• Business Quant data shows SYRE's Change in Accured Expenses at $3.7 million in Q1 2026, $3.1 million in Q4 2025, and $4.4 million in Q3 2025.